What You Should Know:
– This strategic move will fuel Covaris’ growth and expand PerkinElmer’s life sciences portfolio into the high-growth diagnostics market. Notably, both companies share majority ownership under New Mountain Capital, making the integration potentially smoother. While financial details remain undisclosed, the acquisition signifies a significant development in the life sciences landscape.
Fueling the Future of Precision Medicine
With precision medicine gaining momentum in personalized healthcare, Covaris stands at the forefront, enabling the next generation of breakthroughs. Their expertise lies particularly in Next-Generation Sequencing (NGS), offering efficient, reproducible, and high-throughput sample preparation and data analysis. Founded in 1999, Covaris has established itself as a global leader in end-to-end solutions for high-throughput genomic and proteomic analysis, encompassing instruments, consumables, and reagents. This empowers customers across clinical diagnostics, biopharma, and research markets to accelerate their research and drug discovery endeavors.
“Covaris’ well-defined growth strategy, market-leading technologies, and capable leadership team make them an ideal fit for expanding our life sciences portfolio into the diagnostics market,” said Dirk Bontridder, CEO of PerkinElmer. He further emphasizes the significant growth opportunities arising from this merger, fueled by PerkinElmer’s global reach unlocking new commercial avenues for Covaris.